TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer
September 09 2024 - 4:01PM
TriArm Therapeutics (“TriArm” or the “Company”), a clinical-stage,
next-generation cell therapy company leveraging its global presence
and core non-viral platform to advance and democratize CAR-T
therapy for patients worldwide, today announced the appointment of
Douglas E. Williams, Ph.D. as Chief Executive Officer (CEO).
“Doug is an accomplished biopharmaceutical
veteran with over 30 years of cross-functional drug development
expertise, senior corporate leadership experience, proven capital
markets prowess and strategic deal-making savvy, as well as a
strong track record of delivering paradigm-shifting products to
patients, including several blockbusters such as Enbrel®,
Tecfidera®, and Spinraza®,” said James Huang, Founder and Executive
Chairman of the Board of Directors of TriArm. “We are beyond
delighted to welcome Doug as CEO to lead TriArm through our next
phase of growth and have him at the helm as we carry out our
mission of advancing safer, more effective, and lower-cost CAR-T
products for patients around the
world.” “TriArm is
an emerging force in the development of next-generation cell
therapies, and I am excited to join the Company at such a pivotal
time in its journey,” said Dr. Williams. “TriArm’s
foundational non-viral platform, unique R&D strategy and
dedication to democratizing CAR-T therapy create the potential to
address fundamental limitations of today’s commercial CAR-T
armamentarium that have precluded a more profound global impact,
including manufacturing constraints, safety concerns and a limited
number of approved indications. I look forward to working with the
talented team at TriArm to build upon the Company’s impressive
progress to date, driving our differentiated therapies toward
regulatory approval and ultimately to the patients who need them
most.”
Most recently, Dr. Williams served as the
President of Research and Development at Sana Biotechnology, where
he led efforts across the company’s pipeline of gene and cell-based
therapies. Prior to joining Sana, he was the founding Chief
Executive Officer of Codiak BioSciences, where he led the company
through several private financing rounds as well as a successful
IPO. Previously, Dr. Williams served as Executive Vice President of
Research and Development at Biogen, where he played key roles in
the development of novel treatments for neurological disorders,
including Spinraza® and Tecfidera®. He joined Biogen from
ZymoGenetics, where he was Chief Executive Officer and a member of
the Board of Directors, shepherding the company through its
acquisition by Bristol Myers Squibb for $985 million. Before this,
he served as Chief Scientific Officer and Executive Vice President
of Research and Development at Seattle Genetics and Senior Vice
President and Washington Site Leader at Amgen following the
company’s strategic acquisition of Immunex for $16 billion. He
began his career at Immunex where he served in a series of
scientific and senior leadership positions over the course of a
decade. Dr. Williams has served on the board of numerous
biotechnology companies including Ovid Therapeutics, Ironwood
Pharmaceuticals and Regulus Therapeutics, and is currently Chairman
of the Board of AC Immune SA. He holds a Ph.D. from the State
University of New York at Buffalo, Roswell Park Division, and
completed a postdoctoral fellowship at Indiana University School of
Medicine.
About TriArm TherapeuticsTriArm
Therapeutics is a clinical-stage cell therapy company leveraging
its global presence and core non-viral platform to democratize
CAR-T therapy for patients worldwide. Headquartered in San Mateo,
California with R&D, manufacturing and clinical operations hubs
across Europe and Asia, TriArm is executing on its mission to
enable better, safer and more accessible CAR-T products through a
four-pronged approach centered around the company’s (1)
Fast-in-Time™ (FIT™) non-viral platform capable of CAR-T
manufacture in two days, (2) straightforwardly differentiated
programs aimed at clinically- and/or commercially-validated
targets, (3) rapid and efficient clinical translation and
de-risking process via investigator-initiated trials (IITs), and
(4) focus on delivering real benefit to CAR-T eligible patients
currently marginalized by manufacturability issues and prohibitive
cost tied to conventional CAR-T programs. TriArm was founded in
2019 by a team of pharmaceutical veterans with proven drug
development records, and is supported by a top-notch board, leading
scientific and clinical advisors, and long-term investors including
Panacea Venture, MSD Capital, and Lombard Odier. Learn more at
www.triarm.com.
Investor Contact:Christina
TartagliaPrecision
AQ212-362-1200christina.tartaglia@precisionaq.com